Cannabinoids for gastrointestinal diseases: Potential therapeutic applications

Expert Opinion on Investigational Drugs

Volumn 12, Issue 1, 2003, Pages 39-49

  Di Carlo, Giulia ^a   Izzo, Angelo A ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

2 AG; ACEA; Anandamide; Anandamide transport; Cannabinoid agonists antagonists; Cannabinoid receptors; Cannabis; Crohn's disease; Diarrhoea; Emesis; Endocannabinoids; FAAH; Gastric secretion; Gastric ulcer; GERD; Inflammatory bowel disease; Intestinal motility; Intestinal secretion; Intestine; Irritable bowel syndrome; Noladin ether; Paralytic ileus; Rimonabant; SR141716A; Transient lower oesophageal sphincter relaxation; VDM11

Indexed keywords

2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; AM 374; AM 381; ANANDAMIDE; ANTIEMETIC AGENT; CANNABIDIOL; CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; CANNABIS; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DRONABINOL; GLYCEROL DERIVATIVE; INDOLE DERIVATIVE; LEVONANTRADOL; LOPERAMIDE; METHANANDAMIDE; METOCLOPRAMIDE; N (4 HYDROXY 2 METHYLPHENYL)ARACHIDONAMIDE; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; NABILONE; PALMITYLSULFONYLFLUORIDE; PROCHLORPERAZINE; PYRAN DERIVATIVE; RIMONABANT; STEARYLSULFONYLFLUORIDE; TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CROHN DISEASE; DEPRESSION; DIARRHEA; DRUG ACTIVITY; DRUG EFFECT; DRUG HYDROLYSIS; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG STRUCTURE; DYSPHORIA; EUPHORIA; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; HALLUCINATION; HUMAN; INTESTINE MOTILITY; INTESTINE SECRETION; IRRITABLE COLON; NAUSEA; NONHUMAN; PARALYTIC ILEUS; REVIEW; SEDATION; SIDE EFFECT; STOMACH MOTILITY; STOMACH ULCER; VOMITING;

ANIMALS; CANNABINOIDS; ENDOCANNABINOIDS; GASTROINTESTINAL DISEASES; HUMANS; RECEPTORS, CANNABINOID; RECEPTORS, DRUG;

EID: 0037234919     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/eoid.12.1.39.21246     Document Type: Review

References (78)

1. WILLIAMSON EM, EVANS FJ: Cannabinoids in clinical practice. Drugs (2000) 60:1303-1314.
2. GRINSPOON L, BAKALAR JB: Marihuana - the Forbidden Medicine. Yale University Press, New Haven, CT, USA (1997).
3. NOCERINO E, AMATO M, IZZO AA: Cannabis and cannabinoid receptors. Fitoterapia (2000) 71:S6-S12.
4. PORTER AC, FELDER CC: The endocannabinoid nervous system: unique opportunities for therapeutic intervention. Pharmacol. Ther. (2001) 90:45-60.
5. PERTWEE RG, ROSS RA: Cannabinoid receptors and their ligands. Prostaglandins Leucotr. Essent. Fatty Acids (2002) 66:101-121.
6. HOWLETT AC, BARTH F, BONNER TJ et al.: International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. (2002) 54:161-202.
7. MECHOULAM R: Discovery of endocannabinoids and some random thoughts on their possible roles in neuroprotection and aggression. Prostaglandins Leucotr. Essent. Fatty Acids (2002) 66:93-99.
8. GIUFFRIDA A, BELTRAMO B, PIOMELLI D: Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology. J. Pharmacol. Exp. Ther. (2001) 298:7-14.
9. DEVANE WA, DYSARZ FAI, JOHNSON MR, MELVIN LS, HOWLETT AC: Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. (1988) 34:605-613.
10. MATSUDA LA, LOLAIT SJ, BROWNSTEIN BJ, YOUG AC, BONNER TL: Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature (1990) 346:561-564,
11. MUNRO S, THOMAS KL, ABU-SHAAR M: Molecular characterization of a peripheral receptor for cannabinoids. Nature (1993) 365:61-65.
12. DEVANE WA, HANUS L, BREUER A et al.: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science (1992) 258:1946-1949.
13. MECHOULAM R, BEN-SHABAT S, HANUS L et al.: Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to a cannabinoid receptor. Biochem. Pharmacol. (1995) 50:83-90.
14. SUGIURA T. KONDO S, SUKAGAWA A et al.: 2-arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. (1995) 215-.89-97.
15. HANUS L, ABU-LAFI S, FRIDE E et al.: 2-Arachidonyl glyceryl ether, an endogenous agonists of the cannabinoid CB receptor. Proc. Natl. Acad. Sci. USA (2001) 98:3662-3665.
16. ZYGMUNT PM, PETERSSON J, ANDERSSON DA et al.: Vanilloid receptors on sensory nerves mediate the vasodilatator action of anandamide. Nature (1999) 400:452-457.
17. PORTER AC, SAUER JM, KNIERMAN MD et al.: Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB, receptor. Pharmarol. Exp. Ther. (2002) 301:1020-1024.
18. WILSON RI, NICOLL RA: Endocannainoid signaling in the brain. Science (2002) 296:678-682.
19. ELPHICK MR, EGERTOVA M.. The neurobiology and evolution of cannabinoid signalling. Philos. Trans. R. Soc. Lond. B Biol. Sci. (2001) 356:381-408.
20. FOWLER CJ, JACOBSSON SOP: Cellular transport of anandamide, 2-arachidonoylglycerol and palmitoylethanolamide - targets for drug development? Prostaglandins Leucotr. Essent. Fatty Acids (2002) 66:193-200.
21. SUGIURA T, KOBAYASHI Y, OKA S, WAKU K: Biosynthesis and degradation of anandamide and 2-arachidonylglycerol and their possible physiological significance. Prostaglandins Leucotr. Essent. Fatty Acids (2002) 66:173-192
22. DEUTSCH DG, UEDA N, YAMAMOTO S: The fatty acid amide hydrolase (FAAH). Prostaglandins Leucotr. Essent. Fatty Acids (2002) 66:201-210.
23. PERTWEE RG: Cannabinoid and the gastrointestinal tract. Gut (2001) 48:859-897.
24. IZZO AA, MASCOLO N, CAPASSO F: The gastrointestinal pharmacology of cannabinoids. Curr. Opin. Pharmacol. (2001) 1:597-603.
25. PINTO L, CAPASSO R, DI CARLO G, IZZO AA: Endocannabinoids and the gut. Prostaglandins Leucotr. Essent. Fatty Acids (2002) 66:333-341.
26. ADAMI M, FRATI P, BERTINI S et al.: Gastric antisecretory role and immunohistochemical localisation of cannabinoid receptors in the rat stomach. Br. J. Pharmacol. (2002) 135:1598-606.
27. COUTTS AA, IRVING AJ, MACKIE K, PERTWEE RG, ANAVI-GOFFER S: Localisation of cannabinoid CB, receptor immunoreactivity in the guinea pig and rat myenteric plexus. J. Comp. Neurol. (2002) 448:410-422.
28. PINTO L, IZZO AA, CASCIO MG et al.: Endocannabinoids as physiological regulators of colonic propulsion in mice. Gastroenterology (2002) 123:227-234.
29. MASCOLO N, IZZO AA, LIGRESTI A et al.: The endocannabinoid system and the molecular basis of paralytic ileus in mice. FASEB J. (2002) 16:1973-1975.
30. 1-cannabinoid receptor immuncreactivity in the porcine enteric nervous system. Cell Tissue Res. (2000) 302:73-80.
31. KULKARNI-NARLA A, BROWN DR: Opioid, cannabinoid and vanilloid receptor localization on porcine cultured myenteric neurons. Neurosc. Lett. (2001) 308:153-156.
32. 1-receptor mediated regulation of gastrointestinal motility in mice in a chronic model of intestinal inflammation. Br. J. Pharmacol. (2001) 134:563-570.
33. 1 cannabinoid receptors. Br. J Pharmacol. (2001) 134:161-167.
34. STORR M, GAFFAL E, SAUR D, SCHUSDZIARRA V, ALLESHER HD: Effect of cannabinoids on neural transmission in rat gastric fundus. Can. J. Physiol. Pharmacol. (2002) 80:67-76.
35. KATAYAMA K, UEDA N, KURAHASHI Y, SUZUKI H, YAMAMOTO S, KATO I: Distribution of anandamide amidohydrolase in rat tissues with a special reference to small intestine. Biochim. Biophys. Acta (1997) 1347:212-218.
36. PERTWEE RG, FERNANDO SR, GRIFFIN G, ABADJI V, MAKRIYANNIS A: Effect of phenyimethylsulphonyl fluoride on the potency of anandamide as an inhibitor of electrically evoked contractions in two isolated tissue preparations. Eur. J. Pharmacol. (1995) 272:73-78.
37. REGGIO PH: Endocannabinoid structure-activity relationships for interaction at the cannabinoid receptors. Prostaglandins Leucotr. Essent. Fatty Acids (2002) 66:161-172.
38. PERTWEE RG: Cannabinoid receptor ligands: clinical and neuropharmacological considerations relevant to future drug discovery and development. Expert Opin. Invest. Drugs (2000) 9:1553-1571.
39. PIOMELLI D, GIUFFRIDA A, CALIGNANO A, RODRIGUEZ DE FONSECA F: The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol. Sci. (2000) 21:218-224.
40. DE PETROCELLIS L, BISOGNO T, DAVIS JB, PERTWEE RG, DI MARZO V: Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Lett. (2000) 483:52-56.
41. TRAMER MR, CARROL D, CAMPBELL FA et al.: Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ (2001) 323:16-21.
42. GRALLA RA: Cannabinoids and the control of chemotherapy-induced nausea and vomiting. In: Marijuana andMedicine. GC Nahas, KM Sutin, DJ Harvey, S Agurell (Eds), Humana Press, Totowa, NJ, USA (1999).
43. 1 receptor antagonist SR141716A reverses the antiemetic and motor depressant actions of WIN55,212-2. Eur. J. Pharmacol. (2001) 430:49-58.
44. 1 receptors in the least shrew. Pharmacol, Biochem. Behav. (2001) 69:239-249.
45. 1 receptor antagonist/inverse agonist SR141716A. Neuropsycopharmacologv (2001) 150:200-207.
46. 1 receptors in the brainstem of the ferret. Gastroenterology (2001) 121:767-774.
47. FARHADI A, BRUNINGA Y, FIELDS J, KESHAVARZIAN A: Irritable bowel syndrome: an update on therapeutic modalities. Expert Opin. Investig. Drugs (2001) 10:1211-1222.
48. 1 receptors in guinea-pig small intestine. Br. J. Pharmacol. (1996) 118:2199-2205.
49. IZZO AA, MASCOLO N, BORRELLI F, CAPASSO F: Excitatory transmission to the circular muscle of the guinea-pig ileum: evidence for the involvement of cannabinoid CB, receptors. Br. J. Pharmacol. (1998) 124:1363-1368.
50. HEINEMANN A, SHAHBAZIAN A, HOLZER P: Cannabinoid inhibition of guinea-pig intestinal peristalsis via inhibition of excitatory and activation of inhibitory neurla pathways. Neuropharmacology (1999) 38:1289-1297.
51. 1 ligands in the isolated guinea-pig ileum. Br. J. Pharmacol. (2000) 129:984-990.
52. MANCINELLI R, FABRIZI A, DEL MONACO S et al.: Inhibition of peristaltic activity by cannabinoids in the isolated distal colon of mouse. Life Sci. (2001) 69:101-111.
53. 1 receptors in human ileum. Br. J. Pharmacol. (1998) 125:1393-1395.
54. MANARA L, CROCI T, GUAGNINI F et al.: Functional assessment of neuronal cannabinoid receptors in the muscular layers of human ileum and colon. Digest. Liver Dis. (2002) 34:262-269.
55. IZZO AA, MASCOLO N, CAPASSO R, GERMANÒ ME DE PASQUALE R, CAPASSO F: Inhibitory effect of cannabinoid agonists on gastric emptying in the rat. Naunyn-Schmiedebergs Arch. Pharmacol. (1999) 360:221-223.
56. 1 receptors. Eur. J Pharmacol. (1999) 37:187-196.
57. LANDI M, CROCI T, RINALDI-CARMONA M, MAFFRAND J-P, LE FUR G, MANARA L: Modulation of gastric emptying and gastrointestinal transit in rats through intestinal cannabinoid CB, receptors. Eur. J. Pharmacol. (2002) 450:77-83.
58. CALIGNANO A, LA RANA G, MAKRIAYANNIS A, LIN SY, BELTRAMO M, PIOMELLI D: Inhibition of intestinal motility by anandamide, an endogenous cannabinoid. Eur. J. Pharmacol, (1997) 340:R7-R8.
59. COLOMBO G, AGABIO R, LOBINA C, REALI R, GESSA GL: Cannabinoid modulation of intestinal propulsion in mice. Eur. J. Pharmacol. (1998) 344:67-69.
60. 1 ligands in the isolated guinea pig ileum. Naunyn-Scmiedebergs Arch. Pharmacol. (1999) 359:65-70.
61. 2 receptors in intestinal motility in mice. Pharm. Pharmacol. Commun. (2000) 6:287-291.
62. IZZO AA, CAPASSO R, PINTO L, DI CARLO G, MASCOLO N, CAPASSO F: Effect of vanilloid drugs on gastrointestinal transit in mice. Br. J. Pharmacol. (2001) 132:1411-1416.
63. IZZO AA, PINTO L, BORRELLI F, CAPASSO R, MASCOLO N, CAPASSO F. Central and peripheral cannabinoid modulation of gastrointestinal transit in physiological states or during the diarrhoea induced by croton oil. Br. J. Pharmacol (2000) 129:1627-1632.
64. IZZO AA, MASCOLO N, PINTO L, CAPASSO R, CAPASSO F: The role of cannabinoid receptors in intestinal motility, defaecation and diarrhoea in rats. Eur. J. Pharmacol. (1999) 384:37-42.
65. McCALLUM RW, SOYKAN I, SRIDHAR KR, RICCI DA, LANGE RC, PLANKEY MW. Delta-9-tetrahydrocannabinol delays the gastric emptyng of solid food in humans: a double-blind, randomised study. Aliment. Pharmacol. Ther. (1999) 13:77-80.
66. BITTON A, PEPPERCORN MA: Medical management of Crohn's disease. In: Gastrointestinal Pharmacology and Therapeutics. G Friedman, E Jacobson, R McCallum (Eds), Lippincott-Raven, Philadelphia, PA, USA (1997).
67. LIVINGSTON EH, PASSARO EP: Postoperative ileus. Dig. Dis. Sci. 35:121-132.
68. KAHRILAS PJ: Gastroesophageal reflux disease. In: Gastrointestnal Pharmacology and Therapeutics. G Friedman, E Jacobson, R McCallum (Eds), Lippincott-Raven, Philadelphia, PA, USA (1997).
69. FASS R, OFMAN JJ: Gastroesophageal reflux disease-should we adopt a new conceptual framework? Am. J. Gastroenterol. (2002) 97:1901-1909.
70. LEHMANN A, ASHLEY BLACKSHAW L, BRANDEN L et al.: Cannabinoid receptor agonism inhibits transient lower esophageal sphincter relaxations and reflux in dogs. Gastroenterology (2002) 123:1129-1134.
71. CHANG EB: The pathophysiology of diarrhea and constipation. In: Gastrointestinal Pharmacology and Therapeutics. G Friedman, E Jacobson, R McCallum (Eds), Lippincort-Raven, Philadelphia, PA, USA (1997).
72. 1 receptor-mediated in rats. Eur. J. Pharmacol. (2000) 409:207-211.
73. 9-tetrahydrocannabinol in Shay rat test. Pharmacology (1978) 17:173-177.
74. CORUZZI G, ADAMI M, COPPELLI G, FRATI P, SOLDANI G: Inhibitory effect of the cannabinoid receptor agonist WIN 55,212-2 on pentagastrin-induced gastric acid secretion in the anaesthetised rat. Naunyn-Schmiedebergs Arch. Pharmacol. (1999) 360:715-718.
75. 1-mediated inhibition of stress-induced gastric ulcers in rats. Naunyn-Schmiedebergs Arch. Pharmacol. (2001) 363:241-244.
76. NALIN DR, RHEAD J, RENNELS M et al: Cannabis, hypochlorhydria and cholera. Lancet(1978) 2:859-862.
77. CAPASSO R, IZZO AA, FEZZA F et al.: Inhibitory effect of palmitoylethanolamide on intestinal motility in mice. Br. J. Pharmacol. (2001) 134:945-950.
78. SHOOK JE, BURKS TF: Psychoactive cannabinoids reduce gastrointestinal propulsion and motility in rodents. J. Pharmacol. Exp. Ther. (1989) 249:444-449.